Search Results

Bio-Techne Corporation announced that Asuragen, a Bio-Techne brand, will present new data on clinical laboratory testing solutions related to cystic fibrosis variant detection, cancer monitoring, resolving conventionally inaccessible, disease-causing genes, and more at the upcoming meeting of the Association for Molecular Pathology, to be held November 14-18 in Salt Lake City, Utah.

Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, will present its diagnostic lab solutions at the upcoming annual meeting of the Association for Molecular Pathology (AMP), taking place November 1-5 in Phoenix, Ariz.

Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne’s Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation.

Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc. The transaction included initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

Bio-Techne Corporation announced that Asuragen, Inc., a Bio-Techne brand, has launched a new kit to detect pathogenic variants in the CFTR gene.